(Adnkronos) - “Oggi è possibile legare un radioisotopo a un carrier, usandolo in una prima fase diagnostica come tracciante per trovare le alterazioni tumorali. Successivamente al carrier possiamo legare un radioisotopo con funzione terapeutica, per andare a colpire il singolo target nella cellula tumorale e avere una radioterapia mirata per il singolo paziente. Il futuro saranno le combinazioni con altre forme terapeutiche, come ad esempio le immunoterapie”.
Category
🗞
NewsTranscript
00:00Today we are in a new and relevant phase in the treatment of tumors.
00:10We always try to have more treatments that individualize a target and to have the drug
00:17or in the specific case of radiations that can directly hit that target and therefore
00:22hit the neoplastic cell.
00:24With the radioligands we have a carrier to which a radioisotope is linked, a radioisotope
00:32that through this carrier finds cellular alterations within the tumor cells and in
00:38a first phase it is used in the diagnostic phase as a tracer where these altered cells
00:45that capture this radioisotope and therefore become positive are located and this is the
00:49first phase.
00:50To this carrier we can also link a radioisotope and this is the diagnostic side that can have
00:56a therapeutic function, so I have the patient's photograph with all the organs and with the
01:03altered cells and I can link to the carrier at this point a radioisotope with a therapeutic
01:08function and go and hit that single target inside that cell and therefore have
01:15a targeted radiotherapy that therefore hits exactly where I want to hit.
01:21With radiotherapy that today has had a big development with DMRT that allows us to
01:28outline the fields, in any case we outline to wider fields and we do not have exactly
01:35a cognition of those cells that have particular alteration.
01:39Today I can link, in quotation marks, to a mediator a system that is the radioisotope
01:47that emits radiations and therefore I am going to hit those cells and then I can
01:54evaluate with a dosimetry system what is the amount of this radioligand that I can
02:01give to the single patient, for example for metabolic-type problems and therefore go
02:07to a treatment that is extremely targeted for that patient and what we already do today
02:13with the so-called conjugated antibodies, when we connect a drug to the antibody that
02:19goes directly into the cell, is the evolution for nuclear medicine to the carrier, a radioisotope
02:25that hits the cell in a targeted way.
02:28What is the advantage?
02:29That I can give a high dose of irritation, I try to reduce the side effects as much as possible,
02:36but above all then I can go and evaluate over time if my PET turns off, if that treatment
02:42was effective or not.
02:44This is called teragnostics and is the great future, in my opinion, of personalized nuclear medicine.
02:49The platform that we have today is more and more a modulable system, a system that together
02:54with diagnostics, we see it in the head, we see it in the prostate, the tumor, the neuroendocrine tumors,
03:00we had it for the thyroid, therefore having a photograph of the cells that have that
03:05certain marker, that certain target.
03:08On the other hand, having a carrier that can link the radioisotope and therefore hit that
03:13cell, but the future will be the combinations, I mean.
03:17Today we use the radioligand in quotes on our own, we could in the future, having
03:23extremely personalized and targeted treatments, link this treatment, let's think about
03:28immunotherapy, let's think about all the other therapeutic possibilities, so it opens up,
03:33in my opinion, an important prospect for the development of cancer therapy.